Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1

Abstract

Despite recent advances in the detection and treatment of breast cancer, many shortcomings remain, providing incentives to search for new therapeutic targets. This review provides information on the expression and actions of dopamine receptor-1 (D1R) in breast cancer. D1R is overexpressed in a significant number of primary breast tumors, characterized by having an aggressive phenotype and predicting a shorter survival time for patients. Activation of D1R in breast cancer cells by selective agonists caused suppression of cell viability, stimulation of apoptosis, inhibition of cell invasion, and an increase in chemosensitivity. Instead of being linked to the cAMP/PKA system as expected, D1R in breast cancer is linked to the activation of the cGMP/protein kinase G (PKG) pathway. Fenoldopam, a peripheral D1R agonist that does not penetrate the brain, dramatically suppressed the growth of breast cancer xenografts in immune-deficient mice. A new imaging system for detecting D1R-expressing tumors and metastases was also developed. The review offers a novel concept that D1R can serve as a biomarker for prognosis in advanced breast cancer and its agonists can be used as effective and personalized therapeutics in a subpopulation of patients with D1R-expressing breast tumors. Several drugs, some of which are FDA-approved, that bypass the D1R and directly activate the cGMP/PKG apoptotic system, are also identified.

Keywords

Dopamine receptor-1 / cGMP / protein kinase G / phosphodiesterase 5 / xenografts / breast cancer

References

[1] Borcherding DC,Idelman G,Loftus J.Dopamine receptors in human adipocytes: expression and functions..PLoS One2011;6:e25537 PMCID:PMC3180449

[2] Borcherding DC,Hugo ER,Fox S.Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer..Oncogene2016;35:3103-13 PMCID:PMC5541367

[3] Amenta F,Tayebati SK.The peripheral dopaminergic system: morphological analysis, functional and clinical applications..Ital J Anat Embryol2002;107:145-67

[4] Laidler P,Silberring J.Arylsulfatase A in serum from patients with cancer of various organs..Clin Chim Acta1991;204:69-77

[5] Chung KY.Structural aspects of GPCR-G protein coupling..Toxicol Res2013;29:149-55 PMCID:PMC3877993

[6] Sprang SR.Invited review: activation of G proteins by GTP and the mechanism of Galpha-catalyzed GTP hydrolysis..Biopolymers2016;105:449-62 PMCID:PMC5319639

[7] Kebabian JW,Greengard P.Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”..Proc Natl Acad Sci USA1972;69:2145-9 PMCID:PMC426888

[8] Beaulieu JM.The physiology, signaling, and pharmacology of dopamine receptors..Pharmacol Rev2011;63:182-217

[9] Rubi B.Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance..Endocrinology2010;151:5570-81

[10] Reis HJ,Guimaraes MM,Barros AG.Is DARPP-32 a potential therapeutic target?.Expert Opin Ther Targets2007;11:1649-61

[11] Neve KA,Trantham-Davidson H.Dopamine receptor signaling..J Recept Signal Transduct Res2004;24:165-205

[12] Beaulieu JM,Gainetdinov RR.Dopamine receptors - IUPHAR Review 13..Br J Pharmacol2015;172:1-23 PMCID:PMC4280963

[13] Murphy MB,Shorten GD.Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension..N Engl J Med2001;345:1548-57

[14] Windham PF.cGMP signaling as a target for the prevention and treatment of breast cancer..Semin Cancer Biol2015;31C:106-10

[15] Pyriochou A.Soluble guanylyl cyclase: more secrets revealed..Cell Signal2005;17:407-13

[16] Sharma RK.Membrane guanylate cyclase, a multimodal transduction machine: history, present, and future directions..Front Mol Neurosci2014;7:56 PMCID:PMC4079103

[17] Azevedo MF,Bimpaki E,Levy I.Clinical and molecular genetics of the phosphodiesterases (PDEs)..Endocr Rev2014;35:195-233 PMCID:PMC3963262

[18] Courtis F,Charvier K,Journel NM.The control of male sexual responses..Current Pharm Des2013;19:4341-56

[19] Kouvelas D,Papazisis G,Pourzitaki C.PDE5 inhibitors: in vitro and in vivo pharmacological profile..Curr Pharm Des2009;15:3464-75

[20] Wolfertstetter S,Schlossmann J.cGMP-dependent protein kinase inhibitors in health and disease..Pharmaceuticals (Basel)2013;6:269-86 PMCID:PMC3816681

[21] Streff H,Ye Y,Peterson SK.Cancer incidence in first- and second-degree relatives of BRCA1 and BRCA2 mutation carriers..Oncologist2016;21:869-74 PMCID:PMC4943383

[22] Ligresti G,Militello L,Donia M.Breast cancer: molecular basis and therapeutic strategies (Review)..Mol Med Rep2008;1:451-8

[23] Coley HM.Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer..Cancer Treat Rev2008;34:378-90

[24] Fan W,Fu P.Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies..Future Med Chem2015;7:1511-9 PMCID:PMC5558537

[25] Kruser TJ.Mechanisms of resistance to HER family targeting antibodies..Exp Cell Res2010;316:1083-100

[26] Marra A,Curigliano G.Recent advances in triple negative breast cancer: the immunotherapy era..BMC Med2019;17:90 PMCID:PMC6507064

[27] Carlo RD,Bellussi G,Ghi P.Steroid, prolactin, and dopamine receptors in normal and pathologic breast tissue..Ann N Y Acad Sci1986;464:559-62

[28] Sachlos E,Laronde S,Lee JH.Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells..Cell2012;149:1284-97

[29] Minami K,Liu Y,Wan Q.Inhibitory effects of dopamine receptor D1 agonist on mammary tumor and bone metastasis..Sci Rep2017;7:45686 PMCID:PMC5379485

[30] Yang L,Yong L,Su H.Dopamine D1 receptor agonists inhibit lung metastasis of breast cancer reducing cancer stemness..Eur J Pharmacol2019;859:172499

[31] Zhao DL,Lin S,Zhu HB.Anti-apoptotic effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line..Neuropharmacology2007;53:724-32

[32] Moreno-Smith M,Shahzad MM,Allen JK.Dopamine blocks stress-mediated ovarian carcinoma growth..Clin Cancer Res2011;17:3649-59 PMCID:PMC3107884

[33] Chiarenza A,Novi F,Bernardini R.Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1..Eur J Pharmacol2001;433:47-54

[34] Johnson DE,Evans SL.The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells..Anticancer Drugs1995;6:471-4

[35] Chakroborty D,Basu B,Basu S.Catecholamines regulate tumor angiogenesis..Cancer Res2009;69:3727-30

[36] Sarkar C,Mitra RB,Dasgupta PS.Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells..Am J Physiol Heart Circ Physiol2004;287:H1554-60

[37] Okubo Y,Suzuki K,Inoue O.Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET..Nature1997;385:634-6

[38] Chumpradit S,Billings JJ.Synthesis and resolution of (+-)-7-chloro-8-hydroxy-1-(3’-iodophenyl)-3-methyl-2,3,4,5-tetrahydro- 1H-3- benzazepine (TISCH): a high affinity and selective iodinated ligand for CNS D1 dopamine receptor..J Med Chem1991;34:877-83

[39] Zaccolo M.cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology..Circ Res2007;100:1569-78

[40] Fallahian F,Salami S.Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines..FEBS J2011;278:3360-9

[41] Di X,Bear HD,Sheth CM.Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells..Breast Cancer Res Treat2010;124:349-60

[42] Tinsley HN,Keeton AB,Li Y.Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells..Cancer Prev Res (Phila)2011;4:1275-84 PMCID:PMC3151326

[43] Li N,Tinsley HN,Gary BD.Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/beta-catenin signaling..Mol Cancer Ther2013;12:1848-59 PMCID:PMC3800150

[44] Hou Y,Schoenlein P,Martindale R.An anti-tumor role for cGMP-dependent protein kinase..Cancer Lett2006;240:60-8

[45] Shi Z,Patel AS,Chen ZS.Roles of sildenafil in enhancing drug sensitivity in cancer..Cancer Res2011;71:3735-8 PMCID:PMC3107342

[46] Das A,Mitchell C,Hoke NN.Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction..Proc Natl Acad Sci U S A2010;107:18202-7 PMCID:PMC2964209

[47] Roberts JL,Conley A,Malkin M.PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells..Cancer Biol Ther2014;15:758-67 PMCID:PMC4049791

[48] Booth L,Cruickshanks N,Durrant DE.Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells..Mol Pharmacol2014;85:408-19 PMCID:PMC3935155

[49] Das A,Salloum FN,Kukreja RC.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer..Pharmacol Ther2015;147C:12-21 PMCID:PMC4494657

[50] Kitamura K,Star RA,Miller RT.Induction of inducible nitric-oxide synthase by the heterotrimeric G protein Galpha13..J Biol Chem1996;271:7412-5

[51] Kim SG.G-protein signaling in iNOS gene expression..Methods Enzymol2005;396:377-87

[52] Califano JA,Noonan KA,Zhang Z.Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma..Clin Cancer Res2015;21:30-8 PMCID:PMC4329916

[53] Serafini P,Kelso M,Califano J.Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function..J Exp Med2006;203:2691-702 PMCID:PMC2118163

[54] Mankoff DA,Linden HM,Krohn KA.Tumor receptor imaging..J Nucl Med.2008;49 Suppl 2:149S-63

[55] Reddy S.Immuno-positron emission tomography in cancer models..Semin Nucl Med2010;40:182-9 PMCID:PMC2848398

[56] Pennant M,Pennant L,Fry-Smith A.A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence..Health Technol Assess2010;14:1-103

[57] Charpentier S,Severynse DM,Tiberi M.Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties..J Biol Chem1996;271:28071-6

[58] Plouffe B,Laquerre V,Tiberi M.Probing the constitutive activity among dopamine D1 and D5 receptors and their mutants..Methods Enzymol2010;484:295-328

[59] Freedman NJ.Desensitization of G protein-coupled receptors..Recent Prog Horm Res1996;51:319-51

[60] Black LE,Sibley DR.Cyclic AMP-mediated desensitization of D1 dopamine receptor-coupled adenylyl cyclase in NS20Y neuroblastoma cells..Mol Cell Neurosci1994;5:567-75